BV affects over 21 million women in the U.S. each year1,2

While all women can get BV, African-American and Latina women have higher prevalence rates of 53.7% and 31.9%, respectively3

JUST ONE ORAL DOSE

Solosec® (secnidazole) may help your patients complete treatment.

Find out how

REFERENCES:

  1. Chavoustie SE, Eder SE, Koltun WD, et al. Experts explore the state of bacterial vaginosis and the unmet needs facing women and providers. Int J Gynaecol Obstet. 2017;137(2):107-109.
  2. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007;34(11):864-869.
  3. Allsworth JE, Lewis VA, Peipert JF. Viral sexually transmitted infections and bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Sex Transm Dis. 2008;35(9):791-796.
  4. Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017;217(6):678.e1-678.e9. doi: 10.1016/j.ajog.2017.08.017.
  5. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother. 2002;49:897-903.
  6. Bilardi J, Walker S, McNair R, et al. Women’s management of recurrent bacterial vaginosis and experiences of clinical care: a qualitative study. PLoS One. 2016;11(3):e0151794. doi: 10.1371/journal.pone.0151794.
  7. Centers for Disease Control and Prevention. Bacterial vaginosis—CDC Fact Sheet. www.cdc.gov/std/bv/BV-FS-June-2017.pdf. Accessed March 12, 2018.